ADA Scientific Sessions 2026 Abstract

Beyond Glycemic Control: Health-Related Quality-of-Life Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

By Dakshata A. Padhye

Study in peopleInterventions

The paper

Dakshata A. Padhye

Mumbai

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1988-P

doi.org/10.2337/db26-1988-p

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes